|
1
|
Juárez-Salcedo LM, Nimkar S, Corazón AM, Dalia S. Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Int J Mol Sci 2024; 25:7580. [PMID: 39062823 PMCID: PMC11276998 DOI: 10.3390/ijms25147580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2024] [Revised: 07/03/2024] [Accepted: 07/06/2024] [Indexed: 07/28/2024] Open
Abstract
Currently, a significant percentage of patients with DLBCL are refractory or relapse after a first line of immunochemotherapy. Second relapses after autologous stem cell transplantation or chimeric antigen receptor T-cell therapies present few treatment options and do not yield good results. New molecules have entered the immunotherapy arsenal. Loncastuximab tesirine comprises a humanized anti-CD19 monoclonal conjugated antibody, which consists of an anti-CD19 antibody and cytotoxic alkylating agent, SG3199. Several studies have proven its efficacy in the treatment of refractory cases of DLBCL with a good safety profile, with the main adverse effects being neutropenia, thrombopenia, and liver enzyme involvement. In this review, we explain the mechanism of action of this molecule, the clinical data that have led to its acceptance by the FDA, and the new therapeutic options that are proposed in association with this drug.
Collapse
Affiliation(s)
| | - Santosh Nimkar
- College of Osteopathic Medicine, Kansas City University, Kansas City, MO 64804, USA;
| | - Ana María Corazón
- Primary Care Medicine, Adelfas Primary Care Center, 28007 Madrid, Spain;
| | - Samir Dalia
- Hematology/Oncology Department, Mercy Clinic Oncology and Hematology, Joplin, MI 73120, USA
| |
Collapse
|
|
2
|
Hamadani M, Spira A, Zhou X, Liao L, Chen L, Radford J, Ai W, Solh M, Ardeshna KM, Hess B, Caimi PF, Stathis A, Carlo-Stella C, Alderuccio JP, Kahl B, Wang Y, Qin Y, Xu ZC, Zinzani PL. Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial. Blood Adv 2024; 8:93-98. [PMID: 37871303 PMCID: PMC10787240 DOI: 10.1182/bloodadvances.2023010636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Revised: 10/03/2023] [Accepted: 10/03/2023] [Indexed: 10/25/2023] Open
Affiliation(s)
- Mehdi Hamadani
- Division of Hematology and Oncology, BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI
| | | | - Xiaolei Zhou
- RTI Health Solutions, Research Triangle Park, NC
| | - Laura Liao
- ADC Therapeutics America Inc, Murray Hill, NJ
| | - Lei Chen
- ADC Therapeutics America Inc, Murray Hill, NJ
| | - John Radford
- NIHR Clinical Research Facility, University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
| | - Weiyun Ai
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
| | - Melhem Solh
- Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA
| | - Kirit M. Ardeshna
- Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom
| | - Brian Hess
- Department of Medicine, Medical University of South Carolina, Charleston, SC
| | - Paolo F. Caimi
- Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
| | | | - Carmelo Carlo-Stella
- Department of Biomedical Sciences, Humanitas University, Milan, Italy
- Department of Oncology and Hematology, Humanitas Research Hospital−IRCCS, Milan, Italy
| | - Juan Pablo Alderuccio
- Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL
| | - Brad Kahl
- Division of Oncology, Washington University, St. Louis, MO
| | - Ying Wang
- ADC Therapeutics America Inc, Murray Hill, NJ
| | - Yajuan Qin
- ADC Therapeutics America Inc, Murray Hill, NJ
| | | | - Pier Luigi Zinzani
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna, Italy
- Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy
| |
Collapse
|